Intuitive Surgical: This Robotic-Surgery Leader Could Keep Compounding for Another Decade

The company's years of beating the market aren't over yet.Intuitive Surgical (ISRG +0.86%) has faced challenges over the past year.

President Donald Trump's aggressive tariffs are impacting its financial results, and it's now facing more competition than it has arguably ever had in the market for robotic surgery, among other issues. Despite all that, Intuitive Surgical's long-term outlook remains bright. Here's why the stock could deliver superior returns over the next decade. Image source: Getty Images. Moats matter There is one key reason Intuitive Surgical can overcome the obstacles -- the company benefits from a wide moat, based on multiple factors. One is that its famous, market-leading da Vinci system is expensive, requires a steep learning curve, and has been incorporated in many programs to train surgical residents and fellows. The da Vinci system is deeply entrenched in many medical facilities, making it hard for them to switch to a competing device without losing the heavy up-front investment they made to acquire it or the countless hours medical staff invested in training on it. That's one significant advantage. Another is that the da Vinci system has been on the market for over two decades, and there is a wealth of data demonstrating its efficacy and improved patient outcomes across a range of indications. Newcomers to the field may have aced clinical trials to earn clearance, but the real-world data isn't easy to replicate, and grants Intuitive Surgical a leg up. We can also highlight the medical device specialist's innovative capabilities. In 2024, it launched the fifth version of the da Vinci system, with new and improved features. ExpandNASDAQ: ISRGIntuitive SurgicalToday's Change(0.86%) $4.28Current Price$503.81Key Data PointsMarket Cap$179BDay's Range$495.60 - $504.6452wk Range$425.00 - $603.88Volume56KAvg Vol1.9MGross Margin65.98% The future is bright Intuitive Surgical can leverage these advantages to mitigate the effects of tariffs -- perhaps by raising prices slightly, something it can afford to do without losing many customers, thanks to its market leadership. So its installed base should continue growing. Meanwhile, the company should also secure new approvals for the da Vinci system. These label expansions will help increase the device's addressable market. With an expanding installed base and more indications under its belt, its procedure volume should also move in the right direction and help boost revenue and profits. Even with mounting competition, Intuitive Surgical should be fine, especially considering that the market for robotic-assisted surgery is underpenetrated. And over the next decade, we should also see an aging population, which will drive growing demand for many of the procedures handled by the da Vinci system. All these factors (and more) make Intuitive Surgical's prospects strong. Despite the challenges it's faced, the stock remains an excellent pick to hold for the next 10 years.Read NextFeb 20, 2026 •By Reuben Gregg BrewerForget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug WinsFeb 16, 2026 •By Selena MaranjianMy 1 Top AI Healthcare Stock to Buy and Hold ForeverFeb 9, 2026 •By David Jagielski, CPAShould You Buy Intuitive Surgical Stock While It's Under $500?Feb 8, 2026 •By Adria Cimino1 Reason I'd Buy Intuitive Surgical Stock and Never SellFeb 7, 2026 •By Prosper Junior Bakiny2 Top Healthcare Stocks to Buy in FebruaryFeb 7, 2026 •By Reuben Gregg BrewerWhy This Stock's January Slump Could Be a Gift for Patient InvestorsAbout the AuthorProsper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks.

Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various companies. He holds a master’s degree in corporate finance from the University of Maryland Global Campus.TMFPBakinyStocks MentionedIntuitive SurgicalNASDAQ: ISRG$503.81 (+0.86%) $+4.28*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.